BACKGROUND: LC-MS/MS with multiple reaction monitoring (MRM) is a powerful tool for quantifying target analytes in complex matrices. However, the technique lacks selectivity when plasma free metanephrines are measured. We propose the use of multistage fragmentation (MRM
RESULTS:
Over a 6-month period, approximately 1% (n ϭ 21) of patient samples showed uncharacterized coeluting substances that interfered with the routine assay, resulting in an inability to report results. Quantification with MRM 3 removed these interferences and enabled measurement of the target compounds. For patient samples unaffected by interferences, Deming regression analysis demonstrated a correlation between MRM 3 and MRM methods of y ϭ 1.00x Ϫ 0.00 nmol/L for normetanephrine and y ϭ 0.99x ϩ 0.03 nmol/L for metanephrine. Between the MRM 3 method and the median of all LC-MS/MS laboratories enrolled in a quality assurance program, the correlations were y ϭ 0.97x ϩ 0.03 nmol/L for normetanephrine and y ϭ 1.03x Ϫ 0.04 nmol/L for metanephrine. Imprecision for the MRM 3 method was 6.2%-7.0% for normetanephrine and 6.1%-9.9% for metanephrine (n ϭ 10). The lower limits of quantification for the MRM 3 method were 0.20 nmol/L for normetanephrine and 0.16 nmol/L for metanephrine.
CONCLUSIONS:
The use of MRM 3 technology improves the analytical selectivity of plasma free metanephrine quantification by LC-MS/MS while demonstrating sufficient analytical sensitivity and imprecision.
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Liquid chromatography coupled to tandem quadrupole mass spectrometry (LC-MS/MS) is widely used as a powerful tool for quantifying target analytes in clinical chemistry laboratories, owing to the selectivity provided by multiple reaction monitoring (MRM) (1) (2) (3) . 3 However, for a number of assays, interferences exist that can cause falsely increased values when using MRM detection (4 -7 ) .
Enhanced selectivity can be achieved by the use of quadrupole-ion trap tandem mass spectrometers that allow multistage fragmentation (MRM 3 ), in which primary fragment ions, created by collision-induced dissociation, can be isolated and then further fragmented into secondary fragment ions for quantification. Early MRM 3 studies with quadrupole linear ion trap (Q/LIT) instruments focused on characterization and identification in proteomics (8, 9 ) and genomics (10 ) . Newer-generation Q/LIT instruments have demonstrated greater quantitative sensitivity along with reduced cycle times owing to decreased excitation times for MRM 3 experiments (11, 12 ) . These technological advances have made MRM 3 detection more compatible with both the fast liquid chromatography used by modern LC-MS platforms and the sensitivity requirements of quantitative clinical analysis. Recent reports demonstrated that quantitative LC-MS/MS assays with MRM 3 detection could have enhanced selectivity over MRM detection for small molecules and proteins alike (13) (14) (15) . To investigate the possibilities of using MRM 3 detection for clinical chemistry assays, we developed an MRM 3 method for the analysis of plasma free metanephrines to improve the selectivity of our existing LC-MS/MS assay.
Plasma free normetanephrine and metanephrine are first-line screening tests for the diagnosis of pheochromocytoma and paragangliomas (16 -18 ) , which are rare catecholamine-secreting tumors, generally featuring sustained or paroxysmal hypertension, estimated to be prevalent in 0.1%-0.6% of patients presenting with hypertension (19 ) . These tumors can present with a wide range of other symptoms and could be life threatening (20 -22 ) . Very high diagnostic sensitivity means that, with a negative result, these tumors can be ruled out with a high degree of probability. However, as a consequence of the low prevalence of the disease, a lack of analytical selectivity, and suboptimal diagnostic sensitivity, the falsepositive rate is still relatively high.
In recent years, there has been a shift in the methodology of plasma metanephrine measurement to the use of LC-MS/MS in MRM mode (23) (24) (25) (26) . Studies using LC-MS/MS have reported false-positive values that were attributed to preanalytical problems; e.g., blood samples taken with patients in sitting rather than supine position (26 ) . More recent reports describe a number of drug and drug metabolite interferences that can falsely increase, or prevent the measurement of, plasma normetanephrine and metanephrine values determined by LC-MS/MS (5, 6 ) . Petteys et al. demonstrated that the use of quantifier/qualifier ion ratios could provide additional protection from reporting a falsely raised value in these instances (5 ).
In our laboratory, approximately 1% of patient samples show uncharacterized coeluting substances that interfere with our LC-MS/MS assay. To improve the analytical selectivity of our assay, we investigated changes to chromatographic conditions, selection of alternative MRM transitions, and the use of MRM 3 detection. 
Materials and Methods

CHEMICALS AND REAGENTS
D,L-Normetanephrine, D,L-metanephrine, d3-D,
CALIBRATORS AND QC MATERIAL
We created metanephrine-depleted human plasma matrix by pooling excess human plasma, passing aliquots through 3-mL Strata-X-CW SPE cartridges, and repooling the plasma. An aliquot of the eluent was then analyzed to ensure that no metanephrines could be detected. We created a series of spiking solutions containing normetanephrine and metanephrine by diluting stock materials with water. We added 0.3 mL of either water or spiking solution to 29.7-mL aliquots of metanephrine-depleted plasma to create calibrators at 0, 0.28, 1.14, 2.28, 4.55, and 9.10 nmol/L for normetanephrine and 0, 0.14, 0.58, 1.15, 2.3, and 4.60 nmol/L for metanephrine. Plasma metanephrine QC material was purchased from Australian Scientific Enterprise and run with each sample batch to ensure system suitability and imprecision.
PATIENT SAMPLES AND EXTERNAL QUALITY ASSURANCE MATERIAL
Patient EDTA or heparinized plasma samples were stored frozen until analysis. Samples measured in comparison studies were run as part of the routine plasma metanephrine measurement service, with excess sample extracts being reanalyzed by the proposed MRM 3 method. Over a 6-month period, all patient samples demonstrating coeluting interferences in the routine MRM method were stored for later analysis. Approval for analysis and retrospective audits of medical records was obtained from the South Eastern Sydney Local Health District Human Research Ethics Committee. External quality assurance (EQA) free plasma metanephrine material was obtained from the Royal College of Pathologists of Australasia Quality Assurance Program.
SAMPLE PREPARATION
We prepared samples as described previously (5, 26 ) , with 100 L patient sample mixed with 100 L of 10 mmol/L ammonium phosphate buffer containing deuterated internal standards before being loaded onto an Oasis WCX Elution 96-well SPE plate. The metanephrines were later eluted with 3ϫ 30 L of 95:3:2 acetonitrile:water:formic acid.
LC-MS/MS
We performed LC-MS/MS analyses for the routine MRM method as described previously (5, 24, 26, 27 ) with the following alterations. Prepared samples, calibrators, and quality controls (15 L) were injected onto a Prominence HPLC system (Shimadzu) coupled to an API QTRAP 5500 mass spectrometer (ABSciex) operating in positive ion electrospray mode. Chromatographic separation was achieved with an Atlantis 50 ϫ 2.1-mm 3-m HILIC Silica column (Waters). Mobile phase A was 25 mmol/L ammonium formate, pH 3.0, and mobile phase B was acetonitrile. Gradient elution of target analytes was achieved by running 95% B for 1 min followed by ramping to 70% B over 2 min. Normetanephrine eluted at 2.24 min and metanephrine at 2.18 min. Total run time was 7 min.
We quantified target analytes by the routine MRM method by monitoring m/z 1663134 and m/z 1663106 as quantifier and qualifier transitions for normetanephrine, respectively; m/z 1693137 for d3-normetanephrine; m/z 1803148 and m/z 1803165 as quantifier and qualifier transitions for metanephrine; and m/z 1833151 for d3-metanephrine. For the reporting of results above the upper limit for healthy patients, normetanephrine and metanephrine quantifier/qualifier ion ratios from patient samples were required to be within 85%-115% of the mean of the ion ratios recorded from the calibrators. Alternative MRM and MRM 3 transitions monitored during selectivity experiments are summarized in Table 1 . Final MRM 3 transitions were m/z 1663134379 and m/z 16631343116 as quantifier and qualifier transitions for normetanephrine, respectively, and m/z 18031493121 and 1803 1493107 as quantifier and qualifier transitions for metanephrine (Fig. 1) .
Results
INTERFERENCES
Over a 6-month period, 21 patient samples, from a total of 2149, demonstrated coeluting interferences in the routine MRM method that prevented reporting of results. Interferences were detected by either the presence of a closely eluting peak to that of the target analyte, preventing baseline resolution, or by a failed quantifier/qualifier ion ratio. Seven of these patient samples demonstrated a coeluting interference for normetanephrine (5 men, 2 women; age 51-76 years), 12 patients demonstrated coeluting interferences for metanephrine (6 men, 6 women; age 36 -85 years), and 2 patients demonstrated coeluting interferences for both target analytes (1 man, 1 woman; age 26 -65 years).
Previous studies have reported interferences in plasma metanephrine LC-MS/MS assays arising from prescription medications isoproterenol, isoetharine, and labetalol and from illicit substances and metabolites 3,4-methylenedioxy-N-methylamphetamine, 3,4-methylenedioxyamphetamine, and HMMA (5, 6 ) . Retrospective review of medications for the affected patient samples showed that, of the prescribed medications above, only 1 patient was on labetalol. Patients displaying similar interfering peaks had no medications in common that would point to any potential drug being the cause of the interference. In addition, labetalol was ruled out as the source of interference because it demonstrated a different retention time and MRM transition (see results below) from the coeluting peak observed in this patient.
No evidence of substance abuse was reported for any of the patients affected.
CHROMATOGRAPHIC ANALYSIS TO REMOVE INTERFERENCES
Combinations of the following chromatographic experiments were conducted in an attempt to remove the interferences from the affected patient samples: changing mobile phase A buffer concentration (25 mmol/L to 100 mmol/L), pH (3.0 -7.0), and buffer type (ammonium formate to ammonium acetate), along with changing stationary phase from Atlantis HILIC Silica to Ascentis Express HILIC Silica, Ascentis Express OH5, or X-Bridge BEH Amide. All possible permutations were assessed along with the use of shallower gradients. Changes in selectivity between the analyte/interference critical pairs were observed, but no combination of conditions obtained baseline resolution between the interferences and the target analytes in all 21 affected patient samples (data not shown). a Parent ions for normetanephrine and metanephrine were fragmented by collisioninduced dissociation. Primary product ions were isolated and further fragmented to create secondary product ions. MRM transitions were created for each primary product ion, and MRM 3 transitions were created for each secondary product ion. Each MRM and MRM 3 transition was then assessed for selectivity to the target compound. b NA, not applicable.
MRM AND MRM 3 ANALYSIS TO REMOVE INTERFERENCES
Sample extracts from affected patients were further investigated by the selection of different primary product ion fragments for subsequent quantification by MRM analysis ( Table 1 ). The interferences observed in the affected patients were classified by retention time and the effects of different MRMs on signal intensity into 2 groups for normetanephrine, which were named INM1 and INM2 (Fig. 2) , and 4 groups for metanephrine, named IM1, IM2, IM3, and IM4 (Fig. 3) . In the MRM assay, INM1 interfered with the qualifier transition for normetanephrine, causing a failed quantifier/qualifier ion ratio. This interference was removed by detection with an MRM using the m/z 121 product ion. However, INM2 was not removed by any of the MRM transitions monitored. Metanephrine interferences were removed by quantification with MRMs using the following product ions: IM1 m/z 121 and 149; IM2 m/z 120 and 124; IM3 m/z 120 and 124; and IM4 m/z 149. Because no MRM transitions were found to be sufficiently selective for the target analytes, secondary product ions were investigated in quantitative MRM 3 mode by use of the linear ion trap (Table 1) . For normetanephrine, m/z 1663134379 removed both interference groups (Fig. 2) and for metanephrine, m/z 18031493121 removed IM1, IM2, IM3, and IM4 (Fig. 3) . These MRM 3 transitions were then selected for the remainder of the study.
We compared the use of MRM 3 detection to the routine MRM method in a cohort of patients samples with values between 0.2 and 1.8 nmol/L for normetanephrine (n ϭ 44) and between 0.1 and 0.5 nmol/L for metanephrine (n ϭ 23), demonstrating good correlation for both target analytes by Deming regression of MRM 3 ϭ 1.00(MRM, 95% CI 0.92-1.09) Ϫ 0.00 nmol/L for normetanephrine and MRM 3 ϭ 0.99(MRM, 95% CI 0.83-1.15) ϩ 0.03 nmol/L for metanephrine (Fig. 4, A and B) . To ascertain bias while also assessing correlation over a larger range of values, EQA material (n ϭ 23) was measured by the MRM (Fig. 4, C and D) .
The interassay imprecision for 2 concentrations of normetanephrine (0.51 and 2.53 nmol/L) was 5.4% and [M-H 2 O+H] + parent ions for each analyte were mass filtered before being fragmented by collision-induced dissociation. Selected primary product ions were isolated and further fragmented to secondary product ions (*), by use of the linear ion trap functionality (embedded spectrums), to create transitions 1663134379 for normetanephrine and 18031493121 for metanephrine.
4.9% for the MRM method and 7.0% and 6.2% for the MRM 3 method (n ϭ 10), respectively. The interassay imprecision for 2 concentrations of metanephrine (0.23 and 1.10 nmol/L) was 8.3% and 4.3% for the MRM method and 9.9% and 6.1% for the MRM 3 method (n ϭ 10), respectively. Lower limits of quantification (LLOQs) were determined by a signal-to-noise ratio Ͼ10:1, trueness between 80% and 120%, and CV for 20 replicates of Ͻ20%.
For the MRM method, the LLOQ was 0.10 nmol/L for normetanephrine and 0.05 nmol/L for metanephrine, ). To test for MRM 3 selectivity against previously described interferences for LC-MS/MS assays using MRM detection, 50 mol/L isoproterenol, isoetharine, labetalol, and HMMA were spiked into metanephrinedepleted human plasma matrix before extraction and quantification with MRM and MRM 3 detection (Fig. 5) . Consistent with previous findings, there was interference with MRM detection. A small early eluting peak was observed for the normetanephrine quantifier transition m/z 1663134 with isoproterenol (Fig. 5A) . Labetalol displayed a small early eluting peak when monitoring the metanephrine qualifier transition m/z 1803165 (Fig. 5B) . HMMA demonstrated a marked response for the normetanephrine quantifier and qualifier transition m/z 1663106, along with the metanephrine qualifier transition (Fig. 5C ). Isoetharine displayed a small response under the metanephrine quantifier transition m/z 1803148 (Fig. 5D) . A mixture of these 4 compounds did not demonstrate a response above baseline noise when monitoring the MRM 3 transitions selected (Fig. 5, E and F) .
Discussion
Initial attempts at resolving coeluting analyte/interference critical pairs in plasma metanephrine analysis centered on adjustments to the chromatography. HILIC with underivatized silica HPLC columns and a rapid mobile-phase gradient of aqueous ammonium formate (pH 3) and acetonitrile is the most commonly used technique (5, 24 -27 ) . This form of chromatography is highly amenable to LC-MS/MS because of the low back pressures generated, enabling fast chromatography, and the high solvent content of the mobile phase, enhancing the ionization efficiency of the target analytes in the mass spectrometer ion source. Drawbacks to this HILIC methodology arise from the simultaneous mobile- phase gradient of aqueous content, buffer concentration, and apparent pH, leading to reduced chromatographic selectivity. Further complexity is added by the combination of hydrophilic partitioning and ion exchange interactions observed on the chosen stationary phase under HILIC conditions (28 ) . We made adjustments to stationary phase, pH, buffer concentrations, and gradient, but no combination of the chromatographic conditions tested was able to remove all interferences.
Production scans of both normetanephrine and metanephrine demonstrated a number of additional fragments available for MRM transitions. Each fragment was used in an MRM transition to assess for selectivity. The relative intensities of the interferences against the target analytes varied depending on the MRM transition chosen, with some interference peaks becoming undetectable and some increasing as much as 100-fold; however, no transition conferred the selectivity required in all affected samples.
Each fragment, isolated from the product ion scan, was fragmented again in the LIT to look for secondary ion candidates. These secondary ions were selected for MRM 3 transitions and checked for selectivity against the 6 interference groups identified in this study. An MRM 3 transition was identified for normetanephrine and metanephrine that completely removed the interferences in all 21 patient samples. In each case, the reported values for normetanephrine and metanephrine were below the clin- 3 (E, F) detection for normetanephrine and metanephrine. In each chromatogram, the y-axis has been normalized to peak intensities observed when measuring the lower limit of quantification by the respective transitions.
Improved LC-MS Plasma Metanephrine Analysis with MRM ical decision threshold and would have allowed a negative result to be reported.
A comparison between MRM 3 and MRM detection in patients unaffected by interferences demonstrated good agreement between the 2 methods. In addition, analysis of EQA material by the MRM 3 detection method illustrated an agreement with other laboratories measuring plasma free metanephrines by LC-MS/MS. During the validation of the MRM 3 detection method, there was a noticeable decrease in sensitivity compared with MRM detection, with an LLOQ of 0.2 nmol/L for normetanephrine and 0.16 nmol/L for metanephrine, representing 2-fold and 3-fold increases, respectively. In our laboratory, we have determined the upper reference limits for healthy patients to be 0.9 nmol/L for normetanephrine and 0.4 nmol/L for metanephrine, which is similar to previous studies (23 ) ; thus the MRM 3 LLOQ concentrations are sufficient for clinical diagnostic analysis.
The slight increase in interassay imprecision observed for the MRM 3 method at concentrations of clinical importance was within the minimum specifications for imprecision on the basis of biological variation data (25 ) and well within the allowable limits of analytical performance, determined by the EQA program of the Royal College of Pathologists of Australasia (i.e., Ϯ200 pmol/L up to 1000 pmol/L and Ϯ20% for values Ͼ1000 pmol/L for normetanephrine and Ϯ75 pmol/L up to 500 pmol/L and Ϯ15% for values Ͼ500 pmol/L for metanephrine).
The use of MRM 3 transitions for quantification does come with a number of drawbacks. Despite recent advances reducing the cycle time required for MRM 3 analysis, the total cycle time remains considerably longer than that seen in most MRM experiments. This, combined with the accelerated chromatography seen in modern LC-MS applications, limits the number of analytes that can be measured simultaneously while still obtaining enough data points across a chromatographic peak for precise measurement. This phenomenon may explain the higher LLOQ and imprecision described in this report.
The subsequent MRM 3 detection method described in this report proved to be superior in selectivity to MRM detection while still being able to quantify the target analytes at the concentrations required in clinical practice. 
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